Synthetic organic

GW501516 has been used to study its effect on mutation-driven colorectal tumorigenesis and tumor invasion using mouse model. GW501516 has been used as a peroxisome proliferator-activated receptor (PPAR) δ agonist: to treat the differentiated L6

GW501516 has been used to study its effect on mutation-driven colorectal tumorigenesis and tumor invasion using mouse model. GW501516 has been used as a peroxisome proliferator-activated receptor (PPAR) δ agonist: to treat the differentiated L6

GW501516 has been used to study its effect on mutation-driven colorectal tumorigenesis and tumor invasion using mouse model. GW501516 has been used as a peroxisome proliferator-activated receptor (PPAR) δ agonist: to treat the differentiated L6

GW501516 has been used to study its effect on mutation-driven colorectal tumorigenesis and tumor invasion using mouse model. GW501516 has been used as a peroxisome proliferator-activated receptor (PPAR) δ agonist: to treat the differentiated L6

GW501516 has been used to study its effect on mutation-driven colorectal tumorigenesis and tumor invasion using mouse model. GW501516 has been used as a peroxisome proliferator-activated receptor (PPAR) δ agonist: to treat the differentiated L6

GW 5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms.

GW 5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms.

GW 5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms.

GW542573X.

GW542573X.

GW583340.

GW583340.